Citadel Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-15,202
| Closed | -$6.61K | – | 16042 |
|
|
2022
Q4 | $6.61K | Buy |
+15,202
| New | +$4.93K | ﹤0.01% | 13901 |
|
|
2022
Q2 | – | Sell |
-208,065
| Closed | -$86.1K | – | 14632 |
|
|
2022
Q1 | $139K | Buy |
208,065
+73,055
| +54% | +$62K | ﹤0.01% | 11942 |
|
|
2021
Q4 | $174K | Buy |
135,010
+76,470
| +131% | +$136K | ﹤0.01% | 12065 |
|
|
2021
Q3 | $127K | Buy |
58,540
+13,541
| +30% | +$29.4K | ﹤0.01% | 12579 |
|
|
2021
Q2 | $123K | Buy |
44,999
+13,307
| +42% | +$33.1K | ﹤0.01% | 12723 |
|
|
2021
Q1 | $83K | Sell |
31,692
-36,739
| -54% | -$104K | ﹤0.01% | 12619 |
|
|
2020
Q4 | $190K | Buy |
68,431
+5,987
| +10% | +$17.4K | ﹤0.01% | 9779 |
|
|
2020
Q3 | $288K | Sell |
62,444
-704,972
| -92% | -$2.33M | ﹤0.01% | 8210 |
|
|
2020
Q2 | $2.16M | Sell |
767,416
-87,855
| -10% | -$282K | ﹤0.01% | 4426 |
|
|
2020
Q1 | $2.09M | Buy |
855,271
+712,470
| +499% | +$2.57M | ﹤0.01% | 4075 |
|
|
2019
Q4 | $731K | Sell |
142,801
-488,286
| -77% | -$2.71M | ﹤0.01% | 6168 |
|
|
2019
Q3 | $4.08M | Sell |
631,087
-145
| -0% | -$1K | ﹤0.01% | 3390 |
|
|
2019
Q2 | $3.93M | Buy |
631,232
+414,982
| +192% | +$3.16M | ﹤0.01% | 3449 |
|
|
2019
Q1 | $2.3M | Buy |
216,250
+212,178
| +5,211% | +$2.11M | ﹤0.01% | 4224 |
|
|
2018
Q4 | $32K | Buy |
4,072
+1,596
| +64% | +$23K | ﹤0.01% | 8605 |
|
|
2018
Q3 | $48K | Sell |
2,476
-15,180
| -86% | -$276K | ﹤0.01% | 8815 |
|
|
2018
Q2 | $319K | Sell |
17,656
-98
| -0.6% | -$1.45K | ﹤0.01% | 7112 |
|
|
2018
Q1 | $189K | Sell |
17,754
-53,796
| -75% | -$864K | ﹤0.01% | 7400 |
|
|
2017
Q4 | $3.02M | Sell |
71,550
-89,176
| -55% | -$4M | ﹤0.01% | 3089 |
|
|
2017
Q3 | $8.85M | Buy |
160,726
+123,042
| +327% | +$20.8M | 0.01% | 1711 |
|
|
2017
Q2 | $6.99M | Sell |
37,684
-39,943
| -51% | -$7M | 0.01% | 1769 |
|
|
2017
Q1 | $9.28M | Buy |
77,627
+43,543
| +128% | +$4.56M | 0.01% | 1504 |
|
|
2016
Q4 | $3.39M | Buy |
+34,084
| New | +$3.59M | ﹤0.01% | 2373 |
|
|
2016
Q3 | – | Sell |
-71,585
| Closed | -$8.59M | – | 7934 |
|
|
2016
Q2 | $7.35M | Buy |
71,585
+64,052
| +850% | +$6.4M | 0.01% | 1489 |
|
|
2016
Q1 | $692K | Buy |
7,533
+6,597
| +705% | +$704K | ﹤0.01% | 3957 |
|
|
2015
Q4 | $135K | Sell |
936
-3,274
| -78% | -$426K | ﹤0.01% | 6341 |
|
|
2015
Q3 | $435K | Sell |
4,210
-24
| -0.6% | -$2.81K | ﹤0.01% | 4997 |
|
|
2015
Q2 | $691K | Buy |
+4,234
| New | +$718K | ﹤0.01% | 4488 |
|
Other funds holding SIOX
JC
CIA
BBA
Citadel Advisors's SIOX Position: Q1 2023 in Review
Citadel Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 15,202 shares — an estimated $6.61K sold.
Citadel Advisors first reported a position in SIOX in Q2 2015 and held it in 28 quarters. The position peaked at $9.28M in Q1 2017. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.
- Citadel Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 15,202 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $6.61K.
- Citadel Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 28 quarters.
- Citadel Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $9.28M in Q1 2017.
- 4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.